Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 5/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972349 | 1.00 | MME (0.50) | MMENPSR1FPR2NAALAD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL8133191 | 0.98 | MME (0.49) | MMENPSR1FPR2NAALAD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL8133188 | 0.98 | MME (0.49) | MMENPSR1FPR2NAALAD2CYP1A2 | |
| Fluoride SCHEMBL29086588 | 0.97 | MME (0.48) | MMENPSR1FPR2NAALAD2CYP1A2 | |
| SCHEMBL29086585 | 0.94 | MME (0.46) | MMENPSR1FPR2NAALAD2MMP2 | |
| 1,2-Dichlorobenzene SCHEMBL16428571 | 0.91 | ITGB1 (0.51) | MMENPSR1FPR2NAALAD2CYP1A2 | |
| SCHEMBL598433 | 0.87 | FOLH1 (0.50) | MMENAALAD2L3MBTL1 | |
| SCHEMBL9755786 | 0.87 | EPHX1 (0.46) | MMP2 | |
| SCHEMBL598434 | 0.87 | FOLH1 (0.50) | MMENAALAD2L3MBTL1 | |
| SCHEMBL9755788 | 0.87 | EPHX1 (0.46) | MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006017619-A2 | RECEPTOR-BINDING CYCLIC PEPTIDES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060029544-A1 | Receptor-binding cyclic peptides and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2006-02-09 | — | — | US | claimed |
| WO-2024151890-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-06-27 | — | — | US | disclosed |
| EP-4366777-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024080333-A1 | METHOD FOR PRODUCING N-SUBSTITUTED AMINO ACID RESIDUE-CONTAINING CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2024-04-18 | — | — | WO | disclosed |
| WO-2024074813-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MEDICAL LIMITED (GB) | 2024-04-11 | — | — | WO | disclosed |
| CN-116888138-A | Radiopharmaceutical conjugate compositions and uses thereof | 瑞择生物公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230242720-A1 | MODULUS MODIFIERS AND FILMS THEREOF | ZYMERGEN ACQUISITION SUB, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | ZYMERGEN INC. (US) | 2023-08-03 | — | — | US | disclosed |
| EP-0074787-B1 | RENALLY ACTIVE DIPEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1985-03-27 | — | — | EP | disclosed |
| EP-0119705-A2 | Octapeptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1984-09-26 | — | — | EP | disclosed |
| US-4448972-A | Adamantyl containing intermediates | SMITHKLINE BECKMAN CORPORATION (US) | 1984-05-15 | — | — | US | disclosed |
| US-4395401-A | Renally active dipeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-07-26 | — | — | US | disclosed |
| US-4395401-A | Renally active dipeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-07-26 | — | — | US | disclosed |
| US-4387049-A | Adamantyl containing peptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-07 | — | — | US | disclosed |
| EP-0074787-A1 | Renally active dipeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-03-23 | — | — | EP | disclosed |
| EP-0074787-A1 | Renally active dipeptides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-03-23 | — | — | EP | disclosed |
| US-4211783-A | Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | MME 2450/4885NPSR1 1262/4885FPR2 2007/4885 |
| US-20060029544-A1 | Receptor-binding cyclic peptides and methods of use | ITGB3, ITGB5, ITGA5 | MME 3723/4885NPSR1 372/4885FPR2 115/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | MME 2450/4885NPSR1 1262/4885FPR2 2007/4885 |
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | HDHD5, HAO2, ALAD | MME 3058/4885NPSR1 2867/4885FPR2 884/4885 |
| US-20230242720-A1 | MODULUS MODIFIERS AND FILMS THEREOF | SHBG, PTMS, SERPINA6 | MME 766/4885NPSR1 2115/4885FPR2 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.